AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
184.45
+0.07 (0.04%)
At close: Nov 13, 2026, 4:00 PM EST
185.01
+0.56 (0.30%)
After-hours: Nov 13, 2026, 7:58 PM EST

AstraZeneca Revenue

AstraZeneca had revenue of $16.21B in the quarter ending September 30, 2026, with 6.70% growth. This brings the company's total for the last twelve months to $62.38B, up 7.32% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth.

Revenue (ttm)
$62.38B
Revenue Growth
+7.32%
P/S Ratio
4.60
Revenue / Employee
$655,983
Employees
95,100
Market Cap
286.76B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Oncology 25.62B 43.6%
  • BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) 12.77B 21.7%
  • Rare Disease 9.13B 15.5%
  • BioPharmaceuticals: Respiratory & Immunology PR (R&I) 8.87B 15.1%
  • BioPharmaceuticals Infectious Disease PR (ID) 1.27B 2.2%
  • Other Medicines 988.00M 1.7%
  • Collaboration 99.00M 0.2%

By Geography

Chart
  • The Americas 27.56B 46.9%
  • Rest of Europe 13.46B 22.9%
  • Asia, Africa & Australasia 13.37B 22.8%
  • UK 4.36B 7.4%
Fiscal year ended Dec 31, 2025 See the full AstraZeneca breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202558.74B4.67B8.63%
Dec 31, 202454.07B8.26B18.03%
Dec 31, 202345.81B1.46B3.29%
Dec 31, 202244.35B6.93B18.53%
Dec 31, 202137.42B10.80B40.58%
Dec 31, 202026.62B2.23B9.16%
Dec 31, 201924.38B2.29B10.38%
Dec 31, 201822.09B-375.00M-1.67%
Dec 31, 201722.47B-537.00M-2.33%
Dec 31, 201623.00B-1.71B-6.90%
Dec 31, 201524.71B-1.84B-6.93%
Dec 31, 201426.55B741.00M2.87%
Dec 31, 201325.81B-2.17B-7.75%
Dec 31, 201227.97B-5.62B-16.72%
Dec 31, 201133.59B322.00M0.97%
Dec 31, 201033.27B465.00M1.42%
Dec 31, 200932.80B1.20B3.81%
Dec 31, 200831.60B2.04B6.91%
Dec 31, 200729.56B3.08B11.65%
Dec 31, 200626.48B2.53B10.54%
Dec 31, 200523.95B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Johnson & Johnson99.34B
Merck & Co.67.38B
AbbVie66.01B
Pfizer63.62B
Sanofi57.89B
Novartis AG57.36B
Novo Nordisk50.70B
Bristol-Myers Squibb Company50.03B
Revenue Rankings